Adial Pharmaceuticals Inc. (NASDAQ:ADIL) on Tuesday commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans' Access to Emerging Treatments Act.

The bipartisan legislation aims at expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD).

Adial Pharmaceuticals Positioned As Targeted Therapy For Alcohol Use Disorder

Adial's lead investigational product candidate, AD04, is being developed as a genetically targeted therapy for Alcohol Use Disorder.

AD04 follows a non-abstinence-based treatment approach and aligns with FDA-supported endpoints focused on harm reduction and reduction in heavy drinking days, consistent with direction provided by Congress in the federal Appropriations package.

The company said that Alcohol Use Disorder remains a significant issue within the veteran population, with nearly 40% of veterans experiencing AUD at some point in their lives.

Despite the prevalence and impact of the condition, existing Food & Drug Administration-approved treatment options are abstinence-based, limiting therapeutic approaches for many patients.

H.R. 7091 Expands Scope For Emerging AUD Therapies

H.R. 7091 specifically includes AUD among the conditions eligible for expanded research and development efforts.

The legislation supports investigational pharmaceutical therapies that meet the U.S. Government's updated definition of recovery, which includes non-abstinence-based treatment options.

The definition reflects evolving federal policy recognizing harm reduction and reductions in heavy drinking as meaningful clinical outcomes.

Legislative Momentum Builds For Innovative SUD Treatments

The bill has been referred to the House Committee on Veterans' Affairs.

It reflects bipartisan recognition of the need to advance innovative approaches for Substance Use Disorders (SUD), including Alcohol Use Disorder.

Adial believes that H.R. 7091 reinforces federal support for harm reduction-based treatment paradigms and may help advance development efforts for emerging investigational therapies such as AD04.

ADIL Price Action: Adial Pharmaceuticals shares were up 7.61% at $1.98 during premarket trading on Tuesday. The stock is trading near its 52-week low of $1.54, according to Benzinga Pro data.

Image via Company